F

or the second time in recent weeks, a small, privately held drug maker with a piece of the action in two hot markets is being scrutinized by lawmakers over its pricing.

In the latest episode, US Senator Chuck Grassley (R-Iowa) wants Kaleo to explain why it set a $4,500 list price for the Auvi-Q allergic reaction device that is competing with EpiPen. The move is actually part of a complicated pricing strategy that may appeal to some consumers, but not so much to insurers.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Reading their $trategy, it seems that ER’s, municipalities that supply their police and other services would be taking it on the chin. No insurance for them, just a co$t of doing business. Or did I miss something?

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy